Amgen Inc.

Cen Xu

Agnes Eva Hamburger

Chadwick Terence King

Thomas Charles Boone

Shaw-Fen Sylvia Hu

Colin V Gegg

Hsieng Sen Lu

David W Brankow

Licheng Shi

Kenneth William Walker

Derek Evan Piper

Zhulun Wang

Neeraj Jagdish Agrawal

Kevin Graham

Christopher Mohr

Gunasekaran Kannan

Hong Sun

Edward John Belouski

Ling Liu

Dohan Weeraratne

Yuan D Shih

Thomas C Boone

Edward J Belouski

Jr Gegg Colin V

Colin V Gegg Jr

Jr Colin V Gegg

Chadwick T King

Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.

Human CGRP receptor binding proteins

The present invention relates to bispecific antigen binding proteins that are capable of binding to both the human CGRP receptor and the human PAC1 receptor. Pharmaceutical compositions comprising the bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the bispecific antigen binding proteins to ameliorate or treat conditions associated with the two receptors, such as chronic pain, migraine, and cluster headache, are also described.

Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof

The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

Polynucleotides encoding monoclonal antibodies binding to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) and methods of making thereof

The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.

PACAP antibodies and uses thereof

Methods for treating a headache condition using anti-human PAC1 antibodies or antigen-binding fragments thereof

Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.

Human PAC1 antibodies

PAC1 antibodies and uses thereof

Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine.

Growing community of inventors

Newbury Park, CA, United States of America

Cen Xu